De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CSPC Innovation Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Feng Han

Algemeen directeur

CN¥813.7k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.5yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	1.5yrs

Recente managementupdates

Recent updates

Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%

Sep 30

Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)

Aug 16

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk

Jul 04

CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 29

CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32

Apr 25

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable

Apr 24

CEO

Feng Han (50 yo)

1.5yrs

Tenure

CN¥813,700

Compensatie

Mr. Feng Han is GM & Director of CSPC Innovation Pharmaceutical Co., Ltd. from April 07, 2023.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Feng Han	GM & Director	1.5yrs	CN¥813.70k	geen gegevens
Weidong Pan	Chairman	6.8yrs	geen gegevens	geen gegevens
Huaiyu Wang	Non-Independent Director	6.8yrs	geen gegevens	0.0013% CN¥ 543.7k
Lei Cai	Non-Independent Director	1.5yrs	geen gegevens	geen gegevens
Dong Yang	Non-Independent Director	1.5yrs	geen gegevens	geen gegevens
Bing Yao	Non-Independent Director	1.5yrs	geen gegevens	geen gegevens
Dibin Li	Independent Director	1.5yrs	CN¥45.00k	geen gegevens
Peng Yang	Independent Director	1.5yrs	CN¥45.00k	geen gegevens
Congzhi Di	Independent Director	1.5yrs	CN¥45.00k	geen gegevens
Ling Zhang	Non-Employee Supervisor	1.5yrs	geen gegevens	geen gegevens
Jiyong Zhang	Non-Employee Supervisor	1.5yrs	geen gegevens	geen gegevens
Bing Yuan	Employee Supervisor	4.5yrs	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300765 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw bestuur.

CSPC Innovation Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Apr 09, 2024

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Apr 09, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Recent updates

Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%

CSPC Innovation Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 24%

Now 21% overvalued after recent price rise

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.16 in 2Q 2023)

Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)

Now 24% overvalued

Now 20% overvalued

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk

Price target increased by 7.0% to CN¥43.00

CSPC Innovation Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

Consensus EPS estimates fall by 10%

CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture

CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32

Dividend of CN¥0.32 announced

First quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.16 in 1Q 2023)

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable

CSPC Innovation Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Apr 09, 2024

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Apr 09, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 23%

Price target increased by 70% to CN¥49.46

High number of new and inexperienced directors

CSPC Innovation Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 15, 2024

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 34%

Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.16 in 3Q 2022)

Investor sentiment improves as stock rises 20%

CSPC Innovation Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) announces an Equity Buyback for CNY 421.8 million worth of its shares.

CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) announces an Equity Buyback for CNY 421.8 million worth of its shares.

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.20 in 2Q 2022)

CSPC Innovation Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Now 21% undervalued

High number of new and inexperienced directors

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.15 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.14 in 2Q 2021)

CSPC Innovation Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding

Investor sentiment improved over the past week

CSPC Innovation Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on June 7, 2022

First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 1Q 2021)

CSPC Innovation Pharmaceutical Co., Ltd. Approves Cash Dividend (Tax Included) for the Year 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.14 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.20 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.13 in 1Q 2020)

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS CN¥0.71 (vs CN¥0.69 in FY 2019)

New 90-day low: CN¥16.49

CSPC Innovation Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 05, 2021

New 90-day low: CN¥17.89

New 90-day low: CN¥20.37

Third quarter earnings released

Third quarter earnings released

CSPC Innovation Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

New 90-day low: CN¥20.88

First half earnings released

CSPC Innovation Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

CEO